Status:
COMPLETED
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) II
Lead Sponsor:
National Institute on Aging (NIA)
Collaborating Sponsors:
National Human Genome Research Institute (NHGRI)
Conditions:
Alzheimer Disease
Eligibility:
All Genders
18+ years
Brief Summary
The REVEAL II study provides healthy adult children and siblings of Alzheimer's disease patients with genetic testing and information about their own chances of developing the disease. The study will ...
Detailed Description
Alzheimer's disease (AD) is a common, progressive disease affecting memory and cognition. Apolipoprotein E (APOE) has been identified as a genetic factor that may increase the risk of developing Alzhe...
Eligibility Criteria
Inclusion
- Adult children or siblings of people with Alzheimer's disease.
Exclusion
- Adult children or siblings of people with Alzheimer's disease who are unable to visit a study site.
- Persons with currently untreated depression, anxiety or severe mood disturbances.
- Persons with cognitive deficits.
Key Trial Info
Start Date :
May 1 2003
Trial Type :
OBSERVATIONAL
End Date :
September 1 2006
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT00089882
Start Date
May 1 2003
End Date
September 1 2006
Last Update
July 23 2009
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Howard University College of Medicine, National Human Genome Center
Washington D.C., District of Columbia, United States, 20059
2
Boston University School of Medicine, Alzheimer's Disease Center
Boston, Massachusetts, United States, 02118
3
Weill Medical College of Cornell University, Memory Disorders Program
New York, New York, United States, 10021
4
Case Western Reserve University, Memory and Aging Center
Cleveland, Ohio, United States, 44120